Products for Research Use Only
RegisterLogin

Emavusertib

CAT: 0013-GTR19155677-02Size: 500 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19155677-02Size:500 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Emavusertib is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity.
CAS Number
1801344-14-8
Product Name Alternative
CA-4948
Purity
>98% (HPLC)
Solubility
DMSO:27.78 mg/mL (56.52 mM; Need ultrasonic) ; H2O:< 0.1 mg/mL (insoluble)
Smiles
CC1=NC=CC (=C1) C2=NC (=CO2) C (=O) NC3=CC4=C (N=C3N5CC[C@H] (C5) O) N=C (O4) N6CCOCC6
Molecular Formula
C24H25N7O5
Molecular Weight
491.5
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.

Chemical Information

Emavusertib

Emavusertib is an orally bioavailable, reversible inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), with potential antineoplastic, immunomodulating and anti-inflammatory activities. Upon oral administration, emavusertib targets, binds to, and blocks the kinase activity of IRAK4. This inhibits IRAK4-mediated signaling, prevents the activation of IRAK4-mediated nuclear factor-kappa B (NF-kB) signaling and decreases the expression of inflammatory cytokines and certain pro-survival factors. This inhibits proliferation of IRAK4-overactivated tumor cells, which are found in cells harboring MYD88 activating mutations or those with overactivated toll-like receptor (TLR) pathways. In addition, emavusertib may inhibit inflammation and immune-mediated cell destruction in inflammatory and auto-immune diseases where TLR or interleukin 1 receptor (IL-1R) signaling is overactivated and MYD88 is dysregulated. IRAK4, a serine/threonine-protein kinase that plays a key role in both the TLR and IL-1R signaling pathways, is activated though the adaptor protein MYD88 and links the TLR and IL-1R signaling pathway to the NF-kB pathway.

CAS Number1801344-14-8
PubChem CID118224491
IUPAC NameN-[5-[(3R)-3-hydroxypyrrolidin-1-yl]-2-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridin-6-yl]-2-(2-methyl-4-pyridinyl)-1,3-oxazole-4-carboxamide
Molecular FormulaC24H25N7O5
Molecular Weight491.5
XLogP1.7
Topological Polar Surface Area143
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count11
Rotatable Bond Count5
Heavy Atom Count36
Formal Charge0
Complexity773
SMILES
CC1=NC=CC(=C1)C2=NC(=CO2)C(=O)NC3=CC4=C(N=C3N5CC[C@H](C5)O)N=C(O4)N6CCOCC6
InChI
InChI=1S/C24H25N7O5/c1-14-10-15(2-4-25-14)23-27-18(13-35-23)22(33)26-17-11-19-20(28-21(17)31-5-3-16(32)12-31)29-24(36-19)30-6-8-34-9-7-30/h2,4,10-11,13,16,32H,3,5-9,12H2,1H3,(H,26,33)/t16-/m1/s1
InChIKey
SJHNWSAWWOAWJH-MRXNPFEDSA-N
Chemical Structure
2D Structure
2D structure of Emavusertib
CAS: 1801344-14-8
CID: 118224491
Formula: C24H25N7O5
MW: 491.5
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight491.5
XLogP31.7
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count11
Rotatable Bond Count5
Exact Mass491.19171692
Monoisotopic Mass491.19171692
Topological Polar Surface Area143 Ų
Heavy Atom Count36
Formal Charge0
Complexity773
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Alternative Products

CatalogName
462493Emavusertib
HY-135317EEmavusertib (maleate)
A22489-50Emavusertib 50mg
A22489-2Emavusertib 2mg
HY-135317CEmavusertib (tosylate)
T202763-01Emavusertib Mesylate
T202760-01Emavusertib Tosylate
T202252-01Emavusertib Maleate
T86366-01Emavusertib hydrochloride
A22489-25Emavusertib 25mg

Popular Products